文献速递新生儿儿童呼吸

肠内脂质补充对极早产儿严重视网膜病变的影响:一项随机临床试验

Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity: A Randomized Clinical Trial.
PubMed 文献 · JAMA Pediatr · 2021-01-01

IMPORTANCE: Lack of arachidonic acid (AA) and docosahexaenoic acid (DHA) after extremely preterm birth may contribute to preterm morbidity, including retinopathy of prematurity (ROP).…

要点

  • 极早产儿肠内补充AA:DHA可降低严重ROP风险约50%。
  • 补充组血清AA和DHA磷脂 fraction 显著高于对照组。
  • 支气管肺发育不良和脑室内出血发生率组间无显著差异。

核心结论

  • 与标准治疗相比,肠内补充AA:DHA使极早产儿严重ROP风险降低50%,并提高血清AA和DHA水平。

研究设计与样本

  • Mega Donna Mega试验为随机临床试验,在瑞典3所大学医院开展,2016年12月15日至2019年12月15日。
  • 共筛查209名胎龄小于28周的婴儿,纳入206名;AA:DHA组101名(男58名,平均胎龄25.5周),对照组105名(男59名,平均胎龄25.5周)。
  • 疗效分析基于意向治疗人群(按随机分组)和符合方案人群(按实际治疗分组),筛查眼科医生设盲。

主要发现

  • 支气管肺发育不良发生率AA:DHA组48/101(47.5%) vs 对照组48/105(45.7%),任何级别脑室内出血43/101(42.6%) vs 42/105(40.0%),均无显著差异。
  • 败血症AA:DHA组42/101(41.6%) vs 对照组53/105(50.5%),严重不良事件26/101(25.7%) vs 26/105(24.8%),死亡16/101(15.8%) vs 13/106(12.3%)。

关键数值与推荐

  • 干预:肠内补充油剂提供AA 100 mg/kg/d和DHA 50 mg/kg/d,出生后3天内开始至矫正胎龄40周。
  • 主要结局:严重ROP定义为3期和/或1型。

临床怎么用

  • 对于胎龄小于28周的极早产儿,可考虑从出生后早期开始肠内补充AA:DHA以降低严重ROP风险。
  • 补充期间需监测血清AA和DHA水平,并关注其他早产儿并发症的发生率。

局限性

  • 研究仅纳入瑞典3所大学医院的婴儿,外推性需谨慎。
  • 筛查眼科医生设盲,但未提及喂养干预的其他盲法细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Lack of arachidonic acid (AA) and docosahexaenoic acid (DHA) after extremely preterm birth may contribute to preterm morbidity, including retinopathy of prematurity (ROP). OBJECTIVE: To determine whether enteral supplementation with fatty acids from birth to 40 weeks' postmenstrual age reduces ROP in extremely preterm infants. DESIGN, SETTING, AND PARTICIPANTS: The Mega Donna Mega trial, a randomized clinical trial, was a multicenter study performed at 3 university hospitals in Sweden from December 15, 2016, to December 15, 2019. The screening pediatric ophthalmologists were masked to patient groupings. A total of 209 infants born at less than 28 weeks' gestation were tested for eligibility, and 206 infants were included. Efficacy analyses were performed on as-randomized groups on the intention-to-treat population and on the per-protocol population using as-treated groups. Statistical analyses were performed from February to April 2020. INTERVENTIONS: Infants received either supplementation with an enteral oil providing AA (100 mg/kg/d) and DHA (50 mg/kg/d) (AA:DHA group) or no supplementation within 3 days after birth until 40 weeks' postmenstrual age. MAIN OUTCOMES AND MEASURES: The primary outcome was severe ROP (stage 3 and/or type 1). The secondary outcomes were AA and DHA serum levels and rates of other complications of preterm birth. RESULTS: A total of 101 infants (58 boys [57.4%]; mean [SD] gestational age, 25.5 [1.5] weeks) were included in the AA:DHA group, and 105 infants (59 boys [56.2%]; mean [SD] gestational age, 25.5 [1.4] weeks) were included in the control group. Treatment with AA and DHA reduced severe ROP compared with the standard of care (16 of 101 [15.8%] in the AA:DHA group vs 35 of 105 [33.3%] in the control group; adjusted relative risk, 0.50 [95% CI, 0.28-0.91]; P = .02). The AA:DHA group had significantly higher fractions of AA and DHA in serum phospholipids compared with controls (overall mean difference in AA:DHA group, 0.82 mol% [95% CI, 0.46-1.18 mol%]; P < .001; overall mean difference in control group, 0.13 mol% [95% CI, 0.01-0.24 mol%]; P = .03). There were no significant differences between the AA:DHA group and the control group in the rates of bronchopulmonary dysplasia (48 of 101 [47.5%] vs 48 of 105 [45.7%]) and of any grade of intraventricular hemorrhage (43 of 101 [42.6%] vs 42 of 105 [40.0%]). In the AA:DHA group and control group, respectively, sepsis occurred in 42 of 101 infants (41.6%) and 53 of 105 infants (50.5%), serious adverse events occurred in 26 of 101 infants (25.7%) and 26 of 105 infants (24.8%), and 16 of 101 infants (15.8%) and 13 of 106 infants (12.3%) died. CONCLUSIONS AND RELEVANCE: This study found that, compared with standard of care, enteral AA:DHA supplementation lowered the risk of severe ROP by 50% and showed overall higher serum levels of both AA and DHA. Enteral lipid supplementation with AA:DHA is a novel preventive strategy to decrease severe ROP in extremely preterm infants. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03201588.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Hellström A, Nilsson AK, Wackernagel D, et al. Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity: A Randomized Clinical Trial. JAMA Pediatr. 2021. PMID: 33523106. doi:10.1001/jamapediatrics.2020.5653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。